Skip to content

Effect of vitamin D treatment on TSH level, in subclinical hypothyroidism & vitamin D deficient women

Impact of vitamin D treatment on TSH level, in subclinical hypothyroidism & vitamin D deficient women

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT2016062813612N8
Enrollment
25
Registered
2016-09-02
Start date
2016-08-05
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Subclinical hypothyroidism. Iodine-deficiency-related (endemic) goitre, unspecified

Interventions

For patients, vitamin D (50,000 IU capsule per week for 8 weeks) is recommended..
Treatment - Drugs
For patients, vitamin D (50,000 IU capsule per week for 8 weeks) is recommended.

Sponsors

Vice Chancellor for Research of Tabriz University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Criteria for this study: women over 18 years old; patients with subclinical hypothyroidism with TSH higher than 4.5 mlu / L and less than 10 mlu / L; patients with vitamin D deficiency who are defined with 25 (OH) D3 less than 30 mlu / L. Exclusion criteria: patients with systemic diseases (Kidney - lung - Haematic - Digestive); taking medicatiobs that affect on the metabolism of vitamin D; older than 65 years old or younger than 18 years old; being pregnant or plan to become pregnant; patient dissatisfaction to participate in the study.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Thyroid-stimulating hormone(TSH). Timepoint: Baseline and 3 months after treatment. Method of measurement: Test.;Vitamin D. Timepoint: Baseline and 3 months after treatment. Method of measurement: Test.

Secondary

MeasureTime frame
Thyroid Function (FT4). Timepoint: Baseline and 3 months after treatment. Method of measurement: Test.;Thyroid peroxidase antibody. Timepoint: Baseline and 3 months after treatment. Method of measurement: Test.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Farzad Najafipour

Tabriz University of Medical Sciences

farzad278@yahoo.com+98 41 3335 7850

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026